GeneHealth - Your precision medicine

Hypogonadism

Disease Details

Family Health Simplified

Buy Membership

Description: Hypogonadism is a condition in which the body's sex glands produce insufficient sex hormones.
Type: Hypogonadism can be classified into two main types: primary hypogonadism and secondary hypogonadism. Primary hypogonadism, also known as hypergonadotropic hypogonadism, originates from a problem in the testes or ovaries. Secondary hypogonadism, also called hypogonadotropic hypogonadism, results from issues in the hypothalamus or pituitary gland.

The genetic transmission of hypogonadism varies based on the underlying cause. Genetic forms of primary hypogonadism can be inherited in an autosomal dominant, autosomal recessive, or X-linked manner, depending on the specific genetic condition (e.g., Klinefelter syndrome is typically not inherited but arises from a random chromosomal nondisjunction event). Secondary hypogonadism can also be inherited in various patterns, such as autosomal recessive (e.g., Kallmann syndrome). The exact mode of transmission depends on the specific genetic mutations involved.
Signs And Symptoms: Women with hypogonadism do not begin menstruating and it may affect their height and breast development. Onset in women after puberty causes cessation of menstruation, lowered libido, loss of body hair, and hot flashes. In men, it causes impaired muscle and body hair development, gynecomastia, decreased height, erectile dysfunction, and sexual difficulties. If hypogonadism is caused by a disorder of the central nervous system (e.g., a brain tumor), then this is known as central hypogonadism. Signs and symptoms of central hypogonadism may involve headaches, impaired vision, double vision, milky discharge from the breast, and symptoms caused by other hormone problems.
Prognosis: The prognosis for hypogonadism varies depending on the cause, age at diagnosis, and treatment. With appropriate hormone replacement therapy, many individuals can achieve significant symptom relief and maintain a good quality of life. Early diagnosis and treatment are crucial for optimizing outcomes, particularly in adolescents to ensure normal pubertal development, and in adults to prevent complications like osteoporosis and cardiovascular issues. Regular follow-up and adjustments in therapy can help manage the condition effectively over the long term.
Onset: The onset of hypogonadism can vary depending on whether it is congenital or acquired. Congenital hypogonadism is present at birth, whereas acquired hypogonadism can develop at any time due to factors like injury, infection, tumors, or other medical conditions. Symptoms and severity can differ based on the timing and underlying cause.
Prevalence: The prevalence of hypogonadism varies based on the population studied and the criteria used to define the condition. In men, it is estimated that:

- Approximately 2.1% to 5.1% of general adult males are affected.
- The prevalence increases with age, affecting about 20% of men over the age of 60, and up to 30% of men over 70 years old.

Data on the prevalence of hypogonadism in women are less well-defined, but it is generally considered less common than in men.
Epidemiology: Hypogonadism is a medical condition characterized by the body's insufficient production of sex hormones. Epidemiologically, it affects both men and women, though prevalence rates can vary based on age and sex.

In men, the prevalence of hypogonadism increases with age. Studies suggest that approximately 2.1% to 5.6% of younger men (aged 30–79) may be affected, with rates rising significantly in older age groups. For instance, among men aged 45 and older, the prevalence is estimated to be around 38.7%.

In women, hypogonadism prevalence is closely related to menopause and other factors affecting ovarian function. Primary ovarian insufficiency, a form of hypogonadism in women, occurs in approximately 1% of women under the age of 40.

Hypogonadism can result from a variety of causes, including genetic disorders, autoimmune conditions, infections, and injuries affecting the gonads or the hypothalamic-pituitary-gonadal axis. Environmental factors and lifestyle choices, such as obesity and chronic illness, also play a role in its epidemiology.
Intractability: Hypogonadism is not generally considered intractable, as it can often be managed effectively with appropriate medical treatment. Treatments may include hormone replacement therapy, lifestyle changes, and addressing underlying causes. The specific management approach depends on the type and severity of hypogonadism, as well as the patient's overall health. However, long-term or consistent treatment may be necessary to maintain normal hormone levels and manage symptoms.
Disease Severity: Hypogonadism severity can vary greatly depending on the underlying cause, age of onset, and whether it affects males or females. Symptoms can range from mild to severe and include decreased libido, fatigue, muscle weakness, depression, infertility, and delayed or incomplete puberty. Early diagnosis and treatment are important to manage symptoms and improve quality of life.
Healthcare Professionals: Disease Ontology ID - DOID:1924
Pathophysiology: Hypogonadism is a condition characterized by the body's inability to produce normal amounts of testosterone due to a problem with the testes (primary hypogonadism) or with the hypothalamus or pituitary gland (secondary hypogonadism).

Primary hypogonadism:
- Pathophysiology involves dysfunction of the Leydig cells in the testes, which are responsible for testosterone production.
- Common causes include genetic disorders (e.g., Klinefelter syndrome), damage from infections like mumps, trauma, or exposure to radiation or chemotherapy.

Secondary hypogonadism:
- Pathophysiology involves issues in the hypothalamus or pituitary gland, which produce hormones that stimulate the testes to produce testosterone (GnRH, LH, and FSH).
- Causes can include pituitary tumors, systemic illnesses, and chronic conditions like obesity or stress.

In both types, the result is lower levels of circulating testosterone, leading to symptoms such as reduced libido, fatigue, muscle weakness, and possible infertility.
Carrier Status: Hypogonadism is a condition in which the body doesn't produce enough sex hormones. The term "carrier status" typically refers to genetic conditions where an individual carries one copy of a gene mutation that could be passed to offspring. Hypogonadism can have genetic causes, but it's not typically discussed in terms of carrier status as single-gene disorders are. Risk factors and causes can include genetic conditions like Klinefelter syndrome or Turner syndrome, but there isn't a specific "carrier" status for hypogonadism in the traditional sense.
Mechanism: Hypogonadism is a condition characterized by insufficient production of sex hormones, which can affect reproductive and overall health.

**Mechanism:**
1. **Primary Hypogonadism:** This occurs when the gonads (testes in males, ovaries in females) themselves are not functioning properly.
2. **Secondary Hypogonadism:** This results from problems in the hypothalamus or pituitary gland, which are responsible for signaling the gonads to produce hormones.

**Molecular Mechanisms:**
- **In Primary Hypogonadism:** Damage to the gonads due to genetic disorders (such as Klinefelter syndrome or Turner syndrome), injury, infection, or autoimmune conditions can lead to reduced hormone production directly. Mutations in genes such as NR5A1, which encodes Steroidogenic Factor 1 (SF-1), can impair gonadal development and function.
- **In Secondary Hypogonadism:** Dysfunctional secretion of gonadotropin-releasing hormone (GnRH) from the hypothalamus or disrupted release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary can impair gonadal activity. Genetic conditions such as Kallmann syndrome involve mutations in genes like KAL1, affecting GnRH neurons' migration and resulting in reduced GnRH secretion.
- **Hormonal Pathways:** Androgen receptor (AR) gene mutations can lead to androgen insensitivity syndrome, where tissues are unable to respond to androgens.
- **Signal Transduction:** Defects in signaling pathways such as the LH receptor (LHCGR) or FSH receptor (FSHR) can impair the response of gonadal cells to their respective gonadotropins.

Understanding these molecular mechanisms can help in diagnosing and developing targeted treatments for different forms of hypogonadism.
Treatment: Male primary or hypergonadotropic hypogonadism is often treated with testosterone replacement therapy if they are not trying to conceive.In short- and medium-term testosterone replacement therapy does not increase the risk of cardiovascular events (including strokes and heart attacks and other heart diseases). The long-term safety of the therapy is not known yet. Side effects can include an elevation of hematocrit to levels that require blood withdrawal (phlebotomy) to prevent complications from excessively thick blood. Gynecomastia (growth of breasts in men) sometimes occurs. Finally, some physicians worry that obstructive sleep apnea may worsen with testosterone therapy, and should be monitored.While historically, men with prostate cancer risk were warned against testosterone therapy, that has shown to be a myth.Another treatment for hypogonadism is human chorionic gonadotropin (hCG). This stimulates the LH receptor, thereby promoting testosterone synthesis. This will not be effective in men whose testes simply cannot synthesize testosterone anymore (primary hypogonadism), and the failure of hCG therapy is further support for the existence of true testicular failure in a patient. It is particularly indicated in men with hypogonadism who wish to retain their fertility, as it does not suppress spermatogenesis (sperm production) as testosterone replacement therapy does.For both men and women, an alternative to testosterone replacement is low-dose clomifene treatment, which can stimulate the body to naturally increase hormone levels while avoiding infertility and other side effects that can result from direct hormone replacement therapy. Clomifene blocks estrogen from binding to some estrogen receptors in the hypothalamus, thereby causing an increased release of gonadotropin-releasing hormone and subsequently LH from the pituitary. Clomifene is a selective estrogen receptor modulator (SERM). Generally, clomifene does not have adverse effects at the doses used for this purpose.
Compassionate Use Treatment: Hypogonadism, a condition characterized by low testosterone levels, lacks specific compassionate use treatments widely recognized or available. However, several off-label and experimental treatments may be considered under careful medical supervision:

1. **Clomiphene Citrate**: This off-label treatment stimulates the pituitary gland to produce more natural testosterone and is sometimes prescribed for young men who wish to maintain fertility.

2. **Aromatase Inhibitors (e.g., Anastrozole)**: Although not specifically approved for hypogonadism, these drugs can help reduce estrogen levels in men, potentially increasing testosterone levels.

3. **Human Chorionic Gonadotropin (hCG)**: Used off-label, hCG can stimulate the testes to produce testosterone, often used in cases where fertility preservation is a concern.

4. **Selective Androgen Receptor Modulators (SARMs)**: These are experimental treatments still under investigation. They selectively target androgen receptors, aiming to provide the benefits of testosterone with fewer side effects.

It is important to consult with a healthcare provider to thoroughly evaluate the potential benefits and risks of any off-label or experimental treatments for hypogonadism.
Lifestyle Recommendations: For hypogonadism, here are some lifestyle recommendations:

1. **Healthy Diet:** Consume a balanced diet rich in fruits, vegetables, lean proteins, and whole grains to support overall health and hormone production.
2. **Regular Exercise:** Engage in regular physical activity, including both aerobic exercises and strength training, to improve muscle mass, mood, and energy levels.
3. **Weight Management:** Maintain a healthy weight, as obesity can exacerbate hormone imbalances.
4. **Limit Alcohol:** Reduce alcohol intake, as excessive drinking can negatively impact testosterone levels.
5. **Avoid Smoking:** Quit smoking, which can impair hormone production and overall health.
6. **Manage Stress:** Practice stress-reducing techniques such as meditation, yoga, or mindfulness, since chronic stress can affect hormone levels.
7. **Adequate Sleep:** Prioritize good sleep hygiene to ensure 7-9 hours of restful sleep per night, which is crucial for hormone regulation.
8. **Routine Check-ups:** Regularly visit healthcare professionals for monitoring and managing your condition.

These recommendations can help manage symptoms and improve quality of life for individuals with hypogonadism. Always consult with a healthcare provider for personalized advice.
Medication: For male hypogonadism, treatment options often include testosterone replacement therapy (TRT). This can be administered in various forms such as:

1. **Transdermal Patches:** Applied to the skin daily.
2. **Gels:** Applied to the skin, allows for daily testosterone absorption.
3. **Injections:** Administered either intramuscularly or subcutaneously at intervals (e.g., weekly, bi-weekly).
4. **Implantable Pellets:** Placed under the skin every few months.
5. **Oral Medications:** Less common due to liver toxicity concerns.

For female hypogonadism, estrogen replacement therapy (ERT) is often used, combined with progesterone if the woman has not had a hysterectomy. These can be administered as:

1. **Pills:** Taken orally.
2. **Transdermal Patches:** Applied to the skin.
3. **Topical Creams or Gels:** Applied to the skin.
4. **Vaginal Rings:** Placed inside the vagina.

It’s essential for patients to consult healthcare providers to determine the most appropriate and safe treatment regimen.
Repurposable Drugs: Hypogonadism is a condition characterized by low production of sex hormones. Various repurposable drugs can be considered based on underlying causes and patient-specific factors. These include:

1. **Clomiphene Citrate** - commonly used to treat infertility, can stimulate the body to produce more testosterone.
2. **Anastrozole** - an aromatase inhibitor typically used in breast cancer, can prevent the conversion of testosterone to estrogen, thus increasing testosterone levels.
3. **Human Chorionic Gonadotropin (hCG)** - used in fertility treatments, can stimulate the testes to produce more testosterone.

Consult with a healthcare professional for an appropriate diagnosis and treatment plan.
Metabolites: Hypogonadism is a condition where the body doesn't produce enough sex hormones. The primary metabolites involved in hypogonadism depend on whether it affects the testes in men or the ovaries in women. For men, key metabolites include testosterone and its derivatives, such as dihydrotestosterone (DHT) and estradiol. In women, important metabolites include estradiol, progesterone, and, to a lesser extent, testosterone. These metabolites are crucial for the development and maintenance of secondary sexual characteristics, reproductive function, and overall health. Blood tests for these hormone levels are often used to diagnose and manage hypogonadism.
Nutraceuticals: Nutraceuticals refer to food-derived products that provide health benefits beyond basic nutrition, often used to support or improve bodily functions and conditions, including hypogonadism. Some nutraceuticals considered beneficial for managing hypogonadism include:

1. **Zinc:** Essential for testosterone synthesis and overall reproductive health. Deficiency in zinc can lead to decreased testosterone levels.
2. **Vitamin D:** Plays a role in hormone regulation. Adequate levels are associated with higher testosterone levels.
3. **Magnesium:** Crucial for various biochemical reactions, including those involved in hormone production. It also supports testosterone levels.
4. **Ashwagandha:** An adaptogenic herb that helps manage stress hormones and has been shown to increase testosterone levels in some studies.
5. **Fenugreek:** Contains compounds that may support testosterone levels and improve symptoms associated with hypogonadism.
6. **D-Aspartic Acid:** An amino acid that plays a role in the release and synthesis of testosterone.

Before starting any nutraceuticals, it's recommended to consult with a healthcare professional for personalized advice and safety.
Peptides: Hypogonadism is a condition characterized by low levels of sex hormones due to the underactivity of the gonads (testes in men and ovaries in women). Peptides, such as Gonadotropin-Releasing Hormone (GnRH) analogs or Human Chorionic Gonadotropin (hCG), may be used in the treatment of hypogonadism to stimulate hormone production. Nanotechnology isn't typically a standard treatment for hypogonadism, but there is ongoing research into its potential applications, such as drug delivery systems that could improve the efficacy and targeting of treatments.